


PROGRAMME



DIAH

CONFERENCE

INTRODUCTION & OBJECTIVE

There is a clear need in the animal health sector in Europe to bring early developers (academia, research organisations, spin-offs/start-ups) and medium- to big size companies together to facilitate interaction and collaboration between them and thus stimulate innovation.

To fill this gap we will organize a conference differentiating from B2B conferences and focussing on innovation in animal health through collaboration in the phase of pre-development/discovery/proof-of-concept: Discovery to Innovation in Animal Health (DIAH).

The DIAH-conference will be characterised by:

- A limited number of participants (eg max 300 delegates) and more, and more informal, interactions between them
- a focus on co-development and R&D-collaborations between industry and academia/research organisations
 - how to find the right (academic) experts
 - funding: transition from public to public-private funding
 - address regulatory science research needs to facilitate the availability of alternative products to antibiotics, novel vaccines to deal with emerging threats and other novel technologies in a more efficient manner and increase the overall availability of veterinary products
 - multidisciplinary and cross-species (human and animal) approach to innovation
 - valuation and market potential of new technologies: how to come to a fair and realistic deal
 - showcase upcoming technologies, emerging start-ups (in (pre-) incubation phase and the scientific basis of their technology

The goals and objectives of the conference are to

- enable networking among different actors in the field, including researchers, academia, funders, and industry
- improve access of industry to front-edge technologies and expertise in academia
- familiarize researchers with the innovation pipeline process, stages of product development, IP and the regulatory frameworks
- learn young and entrepreneurial researchers to pitch their technology to industry
- align valuation of breakthrough technologies by universities and industry and manage expectations at both sides
- pinpoint differences in culture and objectives between academia and industry, find solutions to overcome them and present best practices of working together
- facilitate researchers scaling up new discoveries/proof of concepts/prototypes to marketable innovations
- show the value of the animal health sector to innovators, funders and industries that are less familiar with the sector but have interesting technologies
- demonstrate the value of interesting ecosystems for innovation in animal health and stimulate collaboration between them
- stimulate (international) public private partnerships for innovation in animal health
- get to know each other better, both when doing business and having fun

PRELIMINARY PROGRAMME

Tuesday, 6 February

12.00 **Registration**

Plenary Room 1+2+3 & Break-out room

13.00 **Workshop: Discovery - Pre Development**

During this workshop, we will zoom in on the phase of Discovery and Pre-Development (TRL-1-4)

TOPIC 1: Find the expert

Steve Nanchen, Head external innovation at Elanco

- How to find the right expert in (large) universities or public research organizations?
- How to establish strong links and collaboration between experts in academia and industry?
- Are any tools available?
- Tips & Tricks

TOPIC 2: Proof of concept

Mathieu Pevrou, CEVA

- What level of POC/TRL is required? Is this different between medium size companies and big pharma companies?
- What are the critical data that should be provided?
- Different requirements for livestock and companion animals

TOPIC 3: Intellectual Property

Stefaan Wera, Virovet

- Is IP need to have or nice to have?
- At what stage do you reach out to industry: invention disclosure (pre-submission), during the priority year, before publication of the patent application, ... ?
- Collaboration, inventionship and ownership of results

The second half of the workshop will be interactive:

- Panel discussion between the speakers and interaction with audience
- Q&A on each of the topics of the presentations

15.00 **Coffee Break**

Plenary Room 1+2+3 & Break-out Room

15.30 **Workshop: Early Development & Valorisation**

During this workshop we will zoom in on the phase of Early Development (TRL 5-6) and Valorisation.

TOPIC 1: Regulatory aspects and GxP

Ana Vidal, EMA

- How does the new animal health law stimulate innovation in animal health
- EMA's innovation task force services and regulatory guidance
- When is GxP relevant/required?
- Can industry provide regulatory guidance?
- Tips & tricks

TOPIC 2: Technology offer and matchmaking

Jan Spaas, Boehringer Ingelheim Animal Health

- What information should a technology offer contain: what does industry want and what can innovators provide?
- Importance of data on mode of action, efficacy, safety, market potential and regulatory aspects.
- At what stage can collaboration start and how can this be funded?

TOPIC 3: Valuation and Deal-Making

Lourdes Mottier, Elanco

- Cost of goods and manufacturing: at what stage should this be considered?
- The cost structure of the development process: from discovery to MAA
- Valuation of innovative and ground-breaking technologies:
 - What if benchmarking is not possible?
 - Should it be risk-adjusted?
- Deal structure
 - Default elements of the deal
 - Differences in function of TRL of the asset

The second half of the workshop will be interactive:

- Panel discussion between the speakers and interaction with audience
- Q&A on each of the topics of the presentations

17.30 **Closing Remarks**

18.00 **Welcome and Opening reception at the City Hall of Ghent**

PRELIMINARY PROGRAMME

Wednesday, 7 February

Plenary Room 1+2

09.00 **Keynote: The Animal Health Industry: market, trends and opportunities for innovation**

Viewpoint from investment banks

TBC

Viewpoint from industry

George Gunn, Stonehaven

TOPICS

- Animal health as an early adopter for new and innovative technologies
- Companies developing technologies for human health, but eager to expand to animal health
- What is coming up in animal health (e.g. targeted therapies for companion animals)?
- What will be the needs/ gaps to fill in the future (e.g. sustainability of the livestock industry, reducing methane production, ...)
- The landscape of technology and how this and veterinary medicine can evolve

Plenary Room 1+2

10.00 **Keynote: New technologies for better vaccines and biologicals**

Emmanuel Hannon, Vicebio

TOPICS

- The landscape of emerging technologies and how these can impact veterinary vaccines (prophylactic and curative, infectious and non-infectious diseases (e.g. diabetes, allergy, cancer)) and biologicals
 - adaptable vaccines (emerging strains and variants) and individualized therapies
 - mRNA/DNA-technology
 - protein/antigen expression, plug & play
 - delivery of the biological (vectors, nanoparticles, targeting ...)
 - Developments that need to occur or are under development to make the technologies viable in an animal health market (i.e. avoid cold chain for mRNA; acceptable cost of goods)
 - Links between new scientific developments and market potential/ needs: where can the technologies bring the solution to unmet needs (e.g. ASF-vaccine, gene therapy, ...)?

11.00 **Coffee Break**

Plenary Room 1+2

11.30

Innovation Spotlight: Emerging technology presenters

Presenters: Entrepreneurial scientists who are developing an innovative animal health application based on a new technology.

Content:

- Focus on new scientific breakthroughs that can lead to innovative applications related to animal health and/or welfare
- Mode of action/scientific basis/soundness of the technology
- Possible applications identified
- Proof of concept at TRL 1-3
- Intellectual property
- First thoughts on cost of goods, regulatory aspects and manufacturing
- Information on business case (market size, competition, ...) is optional

Panel of experts who will select the pitches and will be in the panel at the conference:

- Regulatory experts (regulatory department of animal health companies or EMA/National Agencies)
- External Innovation department of animal health companies
- Scientists (academia and/or industry)

Plenary Room 3 + Break-out Room

13.00

Lunch and One-to-one business partnering

Plenary Room 3 + Break-out Room

14.00

One-to-one business partnering

17.30

Closing Remarks

18.00

Concert and Gala dinner



PRELIMINARY PROGRAMME

Thursday, 8 February

Plenary Room 1 + 2

09.00 **One-to-one business partnering**
Plenary Room 3 + Break-out Room

11.00 **Keynote: Animal health at the cross-road of technologies and industries: diversification and opportunities**
Speaker - Panel: TBC
Plenary Room 1 + 2

TOPICS

- Focus on digital technologies (data & AI)
- Applications
 - o Discovery (e.g. identification of biomarkers, antigens, neoantigens...)
 - o Surveillance and diagnostics

12.00 **Conference Highlights: Workshops & Keynotes**
Plenary Room 1 + 2

12.30 **Lunch & One-to-one business partnering**
Plenary 3 + Break-out Room

13.30

Innovation Spotlight: Emerging start-up presenters

Presenters: Entrepreneurial scientists who are preparing a start-up that wants to market innovative animal health applications based on a new technology.

Content:

- Focus on the gaps/needs in the animal health and/or welfare market that can be met with the technology
- Mode of action/scientific basis/soundness of the technology
- Application that will be developed (timeline)
- Proof of concept at TRL 3-6
- Intellectual property
- Cost of goods, regulatory aspects and chemistry/manufacturing/upscaling
- Information on business case (market size, competition, ...) is required

Panel of experts who will select the pitches and will be in the panel at the conference:

- Regulatory experts (regulatory department of animal health companies or EMA/National Agencies)
- External Innovation department of animal health companies
- Investors



MEET THE SPEAKERS

Emmanuel Hannon



Emmanuel Hanon, PhD, has a background in veterinary medicine and brings over twenty years of experience in vaccine research and development. At GSK, he ran global vaccines R&D for seven years, driving discovery, development, and life-cycle management of one of the largest vaccine portfolios in the industry. He oversaw the discovery and development of vaccines against quadrivalent influenza (Fluarix and Flulaval Quadrivalent), shingles (Shingrix), malaria (Mosquirix), and RSV in older adults. He has been an internal advisor for therapeutic vaccines at Astrivax since the start and will continue to combine his new role as scientific advisory board chair at the company with his role as scientific advisor to CEPI and his CEO role at Vicebio.

PARTNERS



Paul Dick & Associates



Contact:

Sven Arnouts - +32 495 707 334 - Sven.arnouts@UGent.be